Atrial Fibrillation

Atrial fibrillation (AF) occurs in approximately 30% of coronary artery bypass graft (CABG) patients following surgery, increasing cost and morbidity. According to some sources, over $1 billion is spent annually on this problem in the US alone. Current pharmacologic and nonpharmacologic means of AF prevention are suboptimal, and their side-effects, expense, and inconvenience limits their widespread use in all patients. The main focus of this research is the development of a risk stratification method to determine those patients at high risk through the development of electrocardiogram (ECG) features and classification methodologies using intelligent systems. Please see Matthew Wiggins' page [1] for more information.